The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.
The conversation discusses a new study on topical pumpkin seed oil for hair loss in mice. Treatments mentioned include Minoxidil, finasteride, and RU58841.
Users discussed using treatments like minoxidil, finasteride, dutasteride, and exosomes for hair loss. They reported thicker hair and reduced shedding, with some experiencing minor side effects.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
A 25-year-old male experienced increased testosterone and estradiol levels after starting finasteride for hair loss, leading his doctor to suggest a testicular ultrasound as a precaution. The user questions the necessity of the ultrasound, considering it potentially excessive, while others suggest it could be a useful precaution to rule out any issues.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
The conversation is about seeking new research on hair loss treatments beyond the commonly known ones like Minoxidil and Finasteride. Additions to the list of treatments include topical caffeine, alfatradiol, fluridil, stemoxydine, and upcoming treatments like TDM-105795 and verteporfin.
Fluridil, a non-steroidal anti-androgen approved for alopecia in parts of Europe, is noted for its low side effects but is not commonly discussed. The user is inquiring if anyone prefers it over other anti-androgens like Spiro or RU58841.
A user discussed a significant hair recovery using alfatradiol and fluridil but was considered untrustworthy and the post was deleted. They are seeking the original poster's username.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
A user shared their pre-finasteride lab results, including DHT, estradiol, testosterone, SHBG, prolactin, FSH, and LH levels. Another user responded, cautioning against making unsupported claims about side effects and recovery.
There is no reliable ranking for the effectiveness of topical anti-androgens like Fluridil, RU58841, and Pyrilutamide, with limited studies available. Some users suggest Pyrilutamide may be promising based on ongoing trials, while Fluridil combined with finasteride has shown positive results for some individuals.
Hair loss treatments discussed include microneedling, minoxidil, tretinoin, finasteride, dutasteride, pumpkin seeds, saw palmetto, and scalp massage. The consensus is that finasteride or dutasteride is necessary for significant regrowth, while other methods may only slow hair loss.
The user has been using finasteride, dutasteride, and minoxidil without success and is considering a comprehensive blood test to explore other causes of hair loss. They are unsure about the necessity and cost of the extensive tests and are seeking advice on whether to proceed with the full panel or focus on specific tests.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
The user is currently using alfatradiol and fluridil for hair loss and is considering adding low-dose topical finasteride but is concerned about potential side effects due to past mental health issues. They are seeking others' experiences with these treatments and their effectiveness.